AIMS/HYPOTHESIS: Insulin resistance is commonly proposed as a precursor to both type 2 diabetes and cardiovascular disease (CVD), yet few studies have directly compared insulin resistance with both outcomes simultaneously and determined whether associations with each outcome differ in strength or are comparable. We assessed the association of fasting insulin and HOMA-IR with incident CVD and diabetes in older people. METHODS: In the long-term follow-up of the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) cohort, HOMA-IR measurement was available in 4,742 older people (70-82 years) without diabetes at baseline. Of these, 283 developed diabetes during the 3.2 year within-trial follow-up, while 1,943 all-cause deaths, 470 CHD deaths (identified from death records) and 590 fatal/non-fatal CVD events (identified from medical record linkage in the Scottish participants) occurred during an extended 8.6 years of total follow-up. Cause-specific Cox proportional-hazards models were fitted using multivariable models. RESULTS: Higher HOMA-IR was associated with incident diabetes: HR 4.80 (95% CI 3.14, 7.33) comparing extreme thirds after adjustment for confounders. However, HOMA-IR in the top third was not associated with all-cause mortality, CHD mortality or fatal/non-fatal CVD: HR 1.02 (95% CI 0.90, 1.17), 1.03 (0.79, 1.36) and 0.94 (0.74, 1.20), respectively. Results were similar when fasting insulin was considered as an exposure. CONCLUSIONS/ INTERPRETATION: Our data support insulin resistance as a predictor of diabetes in later life but, perhaps surprisingly, suggest this pathway is of negligible importance to CVD outcomes in the elderly.
AIMS/HYPOTHESIS: Insulin resistance is commonly proposed as a precursor to both type 2 diabetes and cardiovascular disease (CVD), yet few studies have directly compared insulin resistance with both outcomes simultaneously and determined whether associations with each outcome differ in strength or are comparable. We assessed the association of fasting insulin and HOMA-IR with incident CVD and diabetes in older people. METHODS: In the long-term follow-up of the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) cohort, HOMA-IR measurement was available in 4,742 older people (70-82 years) without diabetes at baseline. Of these, 283 developed diabetes during the 3.2 year within-trial follow-up, while 1,943 all-cause deaths, 470 CHD deaths (identified from death records) and 590 fatal/non-fatal CVD events (identified from medical record linkage in the Scottish participants) occurred during an extended 8.6 years of total follow-up. Cause-specific Cox proportional-hazards models were fitted using multivariable models. RESULTS: Higher HOMA-IR was associated with incident diabetes: HR 4.80 (95% CI 3.14, 7.33) comparing extreme thirds after adjustment for confounders. However, HOMA-IR in the top third was not associated with all-cause mortality, CHD mortality or fatal/non-fatal CVD: HR 1.02 (95% CI 0.90, 1.17), 1.03 (0.79, 1.36) and 0.94 (0.74, 1.20), respectively. Results were similar when fasting insulin was considered as an exposure. CONCLUSIONS/ INTERPRETATION: Our data support insulin resistance as a predictor of diabetes in later life but, perhaps surprisingly, suggest this pathway is of negligible importance to CVD outcomes in the elderly.
Authors: Soo Lim; Jaeyoung Hong; Ching-Ti Liu; Marie-France Hivert; Charles C White; Joanne M Murabito; Christopher J O'Donnell; Josée Dupuis; Jose C Florez; James B Meigs Journal: Atherosclerosis Date: 2013-04-22 Impact factor: 5.162
Authors: E Bonora; G Targher; M Alberiche; R C Bonadonna; F Saggiani; M B Zenere; T Monauni; M Muggeo Journal: Diabetes Care Date: 2000-01 Impact factor: 19.112
Authors: David Preiss; Paul Welsh; Heather M Murray; James Shepherd; Chris Packard; Peter Macfarlane; Stuart Cobbe; Ian Ford; Naveed Sattar Journal: Eur Heart J Date: 2010-04-15 Impact factor: 29.983
Authors: J Shepherd; G J Blauw; M B Murphy; S M Cobbe; E L Bollen; B M Buckley; I Ford; J W Jukema; M Hyland; A Gaw; A M Lagaay; I J Perry; P W Macfarlane; A E Meinders; B J Sweeney; C J Packard; R G Westendorp; C Twomey; D J Stott Journal: Am J Cardiol Date: 1999-11-15 Impact factor: 2.778
Authors: James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp Journal: Lancet Date: 2002-11-23 Impact factor: 79.321
Authors: David Preiss; Suzanne M Lloyd; Ian Ford; John J McMurray; Rury R Holman; Paul Welsh; Miles Fisher; Chris J Packard; Naveed Sattar Journal: Lancet Diabetes Endocrinol Date: 2013-11-07 Impact factor: 32.069
Authors: X Shen; S He; J Wang; X Qian; H Wang; B Zhang; Y Chen; H Li; Y An; Q Gong; G Li Journal: J Endocrinol Invest Date: 2022-10-11 Impact factor: 5.467
Authors: Anne J Wanders; Wendy A M Blom; Peter L Zock; Johanna M Geleijnse; Ingeborg A Brouwer; Marjan Alssema Journal: BMJ Open Diabetes Res Care Date: 2019-02-08
Authors: Leocadio Rodríguez-Mañas; Javier Angulo; José A Carnicero; Mariam El Assar; Francisco J García-García; Alan J Sinclair Journal: Geroscience Date: 2021-06-01 Impact factor: 7.581
Authors: Carolien Ruijgrok; Jacqueline M Dekker; Joline W Beulens; Ingeborg A Brouwer; Veerle M H Coupé; Martijn W Heymans; Femke P C Sijtsma; David J Mela; Peter L Zock; Margreet R Olthof; Marjan Alssema Journal: Diabetologia Date: 2017-10-10 Impact factor: 10.122